Well this baby is ready to go higher, it is making higher lows and seems very well consolidated. There is an FDA report for an expedite development of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217. This would be the final phase of trials before receiving the right to file a New Drug Application with the FDA and potentially market the drug early next year.
SAGE is focused on the development of products for the treatment of life-threatening central nervous system disorders.
As of now, there are two products under development based on the NMDA (N-methyl-D-aspartate) receptor program: SAGE-718 and SAGE-904.
It looks like a good to go for the rest of the year, be ready to get out at +30% - +40%
SAGE is focused on the development of products for the treatment of life-threatening central nervous system disorders.
As of now, there are two products under development based on the NMDA (N-methyl-D-aspartate) receptor program: SAGE-718 and SAGE-904.
It looks like a good to go for the rest of the year, be ready to get out at +30% - +40%